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The prediction of suicide in severe mental
illness: development and validation of a
clinical prediction rule (OxMIS)
Seena Fazel1, Achim Wolf1, Henrik Larsson2,3, Susan Mallett4 and Thomas R. Fanshawe5
Abstract
Assessment of suicide risk in individuals with severe mental illness is currently inconsistent, and based on clinical
decision-making with or without tools developed for other purposes. We aimed to develop and validate a predictive
model for suicide using data from linked population-based registers in individuals with severe mental illness. A
national cohort of 75,158 Swedish individuals aged 15–65 with a diagnosis of severe mental illness (schizophrenia-
spectrum disorders, and bipolar disorder) with 574,018 clinical patient episodes between 2001 and 2008, split into
development (58,771 patients, 494 suicides) and external validation (16,387 patients, 139 suicides) samples. A
multivariable derivation model was developed to determine the strength of pre-speciﬁed routinely collected socio-
demographic and clinical risk factors, and then tested in external validation. We measured discrimination and
calibration for prediction of suicide at 1 year using speciﬁed risk cut-offs. A 17-item clinical risk prediction model for
suicide was developed and showed moderately good measures of discrimination (c-index 0.71) and calibration. For
risk of suicide at 1 year, using a pre-speciﬁed 1% cut-off, sensitivity was 55% (95% conﬁdence interval [CI] 47–63%) and
speciﬁcity was 75% (95% CI 74–75%). Positive and negative predictive values were 2% and 99%, respectively. The
model was used to generate a simple freely available web-based probability-based risk calculator (Oxford Mental
Illness and Suicide tool or OxMIS) without categorical cut-offs. A scalable prediction score for suicide in individuals with
severe mental illness is feasible. If validated in other samples and linked to effective interventions, using a probability
score may assist clinical decision-making.
Introduction
Suicide risk assessment is currently a central compo-
nent of clinical care in psychiatry1–3, and conducted in
individuals who present to primary and secondary health
services with psychiatric symptoms. Many different
structured tools are used to assist in clinical decision-
making, most of which have not been validated in external
data4, and some of which have poor accuracy5, potentially
increasing workload of clinical teams by identifying false
positives. As a consequence, some experts have suggested
that such tools should not be used, and clinical judgement
be solely used for suicide risk assessment. Further, it has
been argued that identifying high-risk groups might
detract from providing evidence-based clinical care to all
patients, which could be a more effective strategy to
reduce suicide rates6.
However, it remains uncertain whether the alternative—
unstructured clinical approaches without the use of risk-
assessment tools—lead to improved prediction and out-
comes. It has been argued that such tools also provide a
useful baseline assessment, a checklist to identify risk
factors, and can be linked to interventions for higher risk
individuals7,8. In the US, tools are recommended by the
National Strategy for Suicide Prevention9, and the
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European Psychiatric Association has suggested that they
act as adjuncts for clinical assessment10, while in Eng-
land11, Australia and New Zealand12, guidelines argue for
a needs-based assessment over risk assessment for indi-
viduals who present with self-harm. A recent expert
clinical review concludes that new structured approaches
need to be developed and researched, especially for
completed suicide as an outcome8. One important
population with high suicide risks for which there are no
speciﬁc tools are individuals with a severe mental (or
psychotic) illness, namely schizophrenia-spectrum dis-
orders and bipolar disorder13. The risk of suicide in
schizophrenia is around 20 times higher than in the
general population14, contributing to the estimated aver-
age 15 years of potential life lost15, with a range of
modiﬁable risk factors16. In individuals with bipolar dis-
order, a systematic review reported a pooled standardised
suicide mortality ratio of 17 17. In this study, we aim to
develop and externally validate a risk-assessment tool for
suicide in individuals with schizophrenia-spectrum or
bipolar disorder.
Methods
Study sample
We conducted a cohort study of individuals aged 15–65
with a diagnosis of severe mental illness through linkage
of population-based registers in Sweden divided into
derivation and external validation datasets. We included
schizophrenia-spectrum disorders (ICD-8: 295, 297–299;
ICD-9: 295, 297–299 excl. 299A; ICD-10: F20–F29) and
bipolar disorders (296 excl. 296.2; 296 excl. 296D;
F30–F31) diagnoses in the National Patient Register. We
identiﬁed a cohort of 75,158 individuals with 574,018
recorded patient episodes between 1 January 2001 and 31
December 2008. The ﬁnal study cohort consisted of a
single inpatient or outpatient visit for each patient,
selected at random with equal probability, to create a
model that can be used for any patient episode. Repeat
visits were excluded as these would complicate inter-
pretation and model ﬁtting, and we envisaged the tool
being used on a single occasion for each individual rather
than repeatedly over time. Each individual was followed
from the day of discharge until death, emigration or end
of follow-up (12 months post-discharge).
Measurement of risk factors
Individuals within the cohort were linked to national
registers to obtain information on risk factors, with
unique personal identiﬁcation numbers enabling accurate
linkage18. From the Total Population Register19 and
Longitudinal Integration Database for Health Insurance
and Social Studies, we obtained socio-demographic fac-
tors. We identiﬁed psychiatric diagnoses from the
National Patient Register20, and obtained data on
dispensed medication from the Swedish Prescribed Drug
Register21. We further identiﬁed parents and siblings of
patients through the Multi-Generation Register to extract
historical variables (i.e. before the current episode) on
family members (see Appendix pp. 1–2 for details on all
risk factors). From the National Crime Register, we
obtained information on any previous violent conviction.
Measurement of outcomes
Our primary outcome was the occurrence of suicide
within one year. Suicides included undetermined deaths
(i.e. ICD codes X60–84 and Y10–Y34) as is standard in
the ﬁeld of suicide research22. As the cause of death
register covers more than 99% of deaths in Swedish
residents, including those occurring outside Sweden, the
loss of information on suicide was minimal23.
Statistical methods
Statistical analysis was based on multivariable logistic
regression (see below). The effects of non-suicide death
and emigration within the follow-up period were ignored
as the aim was to predict suicide within one year irre-
spective of whether these events occurred, and based only
on information available at the time of episode. STATA
(version 12) and R version 3.2.1 were used for all analyses.
We reported our study based on the TRIPOD reporting
guidelines for prediction models24. We considered
allowing for competing risks but thought that the beneﬁts
would be outweighed by the additional complexity of the
model given the number of censored individuals in the
short follow-up is relatively small.
Risk factors
Based on existing evidence into socio-demographic,
familial, and clinical factors25, we grouped variables a
priori on the anticipated strength of association with the
outcome in decreasing levels of priority26,27. All variables
were categorised in this way in a protocol before any
statistical analysis was carried out (see Appendix p.2 for
description). Table 1 speciﬁes variable groups. Length of
ﬁrst inpatient stay and number of previous episodes were
dichotomised in a pre-speciﬁed way for ease of inter-
pretation. Diagnostic information about individuals and
parental factors was dichotomised to align how it is
reported in clinical practice. Treatment information was
categorised (previous 6 months). Past self-harm was also
dichotomised, although it is possible that information on
number of episodes might have been informative. How-
ever, we were concerned that this may not be available
routinely (due to non-hospital episodes), and subject to
measurement bias. Measures of income and deprivation
were transformed into deciles to enable use in populations
with differences in distribution of income and deprivation,
and where different measures are commonly used. We did
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not test interactions due to limited statistical power
between the 24 tested variables with lack of strong theo-
retical basis to examine speciﬁc ones.
Missing data
Variables with more than 30% missing data were
excluded (body mass index, other physical health vari-
ables, and IQ were not considered for this reason). An
exception was made for the recent treatment information,
which was unavailable before 2006 as the electronic reg-
ister for prescription data was not in operation: the
missingness mechanism was therefore known and
thought to be unrelated to the missing values themselves.
Missing data was imputed via multiple imputation with 20
imputations using a regression model that used as
explanatory variables all other risk factors that were
candidates for inclusion in the model, and the outcome
variable28. Estimates of coefﬁcients in the ﬁnal prediction
rule were obtained by pooling across imputations, using
standard methodology29.
Validation and goodness of ﬁt
The patient cohort was split into separate model
development and external validation datasets, to allow
external validation using individuals not used in model
development. The sample was split based on a stratiﬁed
random selection of geographical regions30, based on the
residential geographical location of the individual at the
time of diagnosis with the external validation dataset
Table 1 Baseline characteristics of the derivation sample
(n= 58,771) diagnosed with schizophrenia-spectrum and
bipolar disorders with grouping of suicide risk factors
Group Variable
1 Sex (male) 29,077 (49%)
1 Age at discharge (SD) 44 (13)
1 Previous violent crime 9212 (16%)
1 Previous drug use 7123 (12%)
1 Previous alcohol use 8897 (15%)
1 Previous self-harm 11,510 (20%)
1 Educational level
Primary 17,814 (35%)
Secondary 26,449 (52%)
Tertiary 6489 (13%)
1 Parental drug or alcohol use 5214 (11%)
1 Parental suicide 1417 (3%)
2 Diagnosis
Schizophrenia-spectrum
disorders
36,755 (63%)
Bipolar disorder 22,016 (37%)
2 Recent medication trethose
with a schizophreniaatment
(within preceding 6 months)
Mood stabiliser 10,390 (32%)
Antipsychotic 18,401 (54%)
Antidepressant 13,255 (39%)
Drug and alcohol
dependence
1030 (3%)
2 Inpatient at time of
assessment
18,160 (31%)
2 Length of ﬁrst inpatient stay >
7 days
24,532 (42%)
2 Number of episodes > 7 16,686 (28%)
3 Beneﬁt receipt 37,210 (64%)
3 Deprivation (illustrative)
1st decile (lowest) 2793 (5%)
5th decile 4862 (9%)
10th decile (highest) 10,769 (19%)
3 Marital status: never married 34,506 (60%)
3 Personal income (illustrative)
1st decile (lowest) 5444 (9%)
5th decile 9169 (16%)
10th decile (highest) 2009 (3%)
Table 1 continued
Group Variable
3 Children in household 11,079 (19%)
3 Parental psychiatric
hospitalisation
13,225 (28%)
3 Parental violent crime 3203 (7%)
3 Sibling violent crime 4028 (7%)
3 Comorbid depression 11,934 (32% of those with a
schizophrenia-spectrum
diagnosis)
3 Recent death of family
member (within preceding
6 months)
953 (2%)
Note: Group 1 refers to variables included in model on the basis of previous
evidence, Group 2 variables with strong evidence but needed validation, Group
3 variables with weaker evidence that we tested. Number (%) or mean (SD).
Missing values are excluded from the denominator in the calculation of the
percentages in the above table. Variables with substantial percentages of
missing data: educational level (14%), parental drug or alcohol use (18%),
parental violent crime (18%), beneﬁt receipt (1.5%), deprivation (3.7%), marital
status (2.2%), personal income (1.5%), parental psychiatric hospitalisation (18%),
parental suicide (18%), recent treatment (54%) and recent death of family
member (18%)
Fazel et al. Translational Psychiatry            (2019) 9:98 Page 3 of 10    98 
comprising around one-ﬁfth of the total sample. The
number of regions selected for the validation sample was
chosen to be large enough for a useful assessment of
external validity to be conducted31 (see Appendix Table
1).
Statistical methods for validation
The internal validity of the model was assessed using
bootstrapping to assess its predictive accuracy32. Boot-
strapping was used to create 100 samples drawn with
replacement from the derivation data-set; more bootstrap
samples were not required as model performance mea-
sures were found to be very similar in different samples. A
heuristic shrinkage estimate (model χ2–degrees of free-
dom]/model χ2) was calculated to assess the gen-
eralisability of the model33. Model performance was also
assessed using the external validation sample. Predictive
accuracy was summarised using the following measures:
(1) the concordance index34 to assess discrimination
(ability of the model to distinguish between those who do
and do not die from suicide, with a value of one meaning
perfect discrimination); (2) the Brier score35 for calibra-
tion (model goodness of ﬁt—whether the predicted risk
systematically off target, with zero meaning perfect cali-
bration); (3) the net reclassiﬁcation index36 (how well a
model rightly or wrongly reclassiﬁes patients compared
with alternative models), and (4) sensitivity and speciﬁcity
based on a 1% threshold of predicted probability. The
choice of this 1% threshold was based on previous
research that found 0.6% of schizophrenia-spectrum
patients dying from suicide within one year of diag-
nosis37. These measures were calculated using the pre-
dicted probabilities obtained by averaging the predictions
from each of the multiply imputed datasets, each applied
to the ﬁnal model. The proportions of predicted and
observed events at different levels of predicted probability
were compared using a calibration plot. A p-value of <0.1
was used to determine statistical signiﬁcance for variable
selection. On the suggestion of a peer reviewer, we also
considered using lasso to address possible overﬁtting.
Web calculator
We applied variable coefﬁcients (Table 2) to develop a
web calculator called OxMIS (Oxford Mental Illness and
Suicide tool).
Ethics approval
Anonymized data was received from Statistics Sweden
following Regional Research Ethics Committee approval
at Karolinska Institutet (2013/5:8). The linkage code was
destroyed when linkage was made. Thus no individual
consent was required.
Results
Of the cohort of 75,158 patients with schizophrenia-
spectrum or bipolar disorder, 16,387 were assigned to the
validation sample and the remainder to the derivation
sample. Baseline characteristics of the derivation sample
are shown in Table 1. In the derivation sample, 494
individuals (0.8%) died of suicide within 12 months of
their patient episode. The validation sample was based on
16,387 patients, and 139 suicides.
Predictors of suicide
The strongest predictors of suicide within 12 months
included being an inpatient at the time of assessment/
diagnosis (OR= 2.95, 95% CI 2.45–3.55), previous self-
harm (OR= 2.55, 95% CI 2.09–3.11) and being male (OR
= 1.92, 95% CI 1.58–2.33) (Table 2). The decline in
probability of suicide was approximately linearly related
to increasing age. The average estimate of the shrinkage
heuristic from the bootstrapped samples was 96% so the
Table 2 Associations between prespeciﬁed risk factors
and suicide in the derivation sample from the multiple
regression model (after multiple imputation)
Variable Odds ratio [95% CI] p-Value
Sex—male 1.92 [1.58, 2.33] <0.001
Age (per 10 years) 0.92 [0.85, 0.99] 0.02
Previous violent crime 0.78 [0.60, 1.02] 0.07
Previous drug use 1.09 [0.84, 1.41] 0.54
Previous alcohol use 1.29 [1.02, 1.63] 0.03
Previous self-harm 2.55 [2.09, 3.11] <0.001
Educational level
Upper secondary 1.24 [1.00, 1.53] 0.05
Post-secondary 1.68 [1.24, 2.28] <0.001
Parental drug or alcohol use 0.70 [0.50, 0.99] 0.04
Parental suicide 1.75 [1.14, 2.69] 0.01
Recent treatment—antipsychotic 1.29 [0.98, 1.69] 0.07
Recent treatment—
antidepressant
1.75 [1.29, 2.38] <0.001
Inpatient at the time of
assessment
2.95 [2.45, 3.55] <0.001
Length of ﬁrst inpatient stay >
7 days
1.23 [1.00, 1.50] 0.05
Number of previous episodes > 7 0.77 [0.61, 0.97] 0.03
Beneﬁt receipt 0.83 [0.67, 1.02] 0.07
Parental psychiatric
hospitalisation
1.20 [0.97, 1.48] 0.10
Comorbid depression 1.27 [1.03, 1.56] 0.03
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coefﬁcients from the development model were used
without shrinkage (Table 2).
The ﬁnal model was arrived at by including all the factor
1 variables, and those factor 2 and 3 ones that retained
statistical signiﬁcance in the multivariable analyses (see
Fig. 1 for a ﬂow chart of model development): sex, age,
previous violent crime, drug use, alcohol use, self-harm,
educational level, parental drug or alcohol use, parental
suicide, recent antipsychotic treatment, antidepressant
treatment, inpatient diagnosis, length of ﬁrst inpatient
stay, number of previous episodes, beneﬁt recipiency,
parental psychiatric hospitalisation, and comorbid
depression (in those with schizophrenia-spectrum dis-
orders). Variables included in the ﬁnal 17-item model are
shown in Table 2 (for full untransformed model coefﬁ-
cients, see Appendix Table 2).
The model showed good overall discrimination, based
on both the results from internal validation using boot-
strapping (c-index= 0.75 [95% CI 0.73–0.77], Brier score
= 0.0082, net reclassiﬁcation index= 0.67) and the results
from external validation (c-index= 0.71 [95% CI
0.66–0.75], Brier score= 0.0084, net reclassiﬁcation
index= 0.51) (see Fig. 2 for ROC curves). When using the
pre-speciﬁed 1% risk cut-off for suicide within one year,
the sensitivity and speciﬁcity were 58% (95% CI 54–63%)
and 76% (95% CI 76–76%), respectively, in internal vali-
dation. The sensitivity in external validation was slightly
lower (55%, 95% CI 47–63%), with similar speciﬁcity (75%,
95% CI 74–75%). The positive predictive value and
negative predictive value were 2% and 99%, respectively
(see Table 3 for 2 × 2 tables).
Calibration plots (Fig. 3) indicate adequate calibration of
the predicted probabilities against observed proportions
of suicide, based on estimated and observed risks being
approximately similar, except for groups with few
patients.
Lasso did not lead to any substantial improvement in ﬁt,
with levels of shrinkage similar to those indicated by the
shrinkage heuristic from our original model (with a
median reduction of 4%, the same as the shrinkage
heuristic in our original model).
Web calculator
A beta version of the online risk calculator for suicide
(based on the coefﬁcients in Appendix Table 2) can be
found at http://oxrisk.com/oxmis for use by clinicians. If
missing values are present, this calculator reports the
upper and lower range of estimates of risk allowing for
missing variables. The calculator presents probabilities
scores, but not cut-offs (as discussed below).
Derivaon sample 
(n=58,771)
Fit model
Update model
Update to ﬁnal 
model
Evaluate 
performance of 
ﬁnal model
External validaon 
sample (n=16,387)
Group 1 variables
Sex
Age at discharge
Previous violent crime
Previous  drug use
Previous  alcohol use
Previous  self-harm
Educaonal level
Parental drug or alcohol use
Parental suicide
Group 2 variables
Diagnosis
Recent medicaon treatment
Inpaent at me of episode
Length of ﬁrst inpaent stay
Number of episodes
Group 3 variables
Beneﬁt receipt
Deprivaon
Marital status
Personal income
Children in household
Parental psychiatric hospitalisaon
Parental violent crime
Sibling violent crime
Comorbid depression
Recent death of family member
Excluded variables
Diagnosis
Excluded variables
Deprivaon
Marital status
Personal income
Children in household
Parental violent crime
Sibling violent crime
Recent death of family member
Fig. 1 Flow chart of analytic approach to model development and validation
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Discussion
This study presents the development and validation of a
clinical risk score for suicide in individuals with severe
mental illness. The validation sample was based on 16,387
patients, and 139 suicides. The score is based on 17 items,
which are mostly routinely collected, including markers of
illness severity and comorbidity, and recent medication.
To our knowledge, this is the ﬁrst such prediction score
developed in individuals with schizophrenia-spectrum
disorders and bipolar disorder. In the external validation,
an overall c-index of 0.71 was reported using a cut-off,
and it performed moderately well on calibration (with
probability scores).
On the basis of the low positive predictive value and a
sensitivity of 55% based on a pre-speciﬁed cut-off score of
1% suicide risk, we have removed the possibility of using it
with a dichotomous risk category, and instead have made
the tool available with the continuous probability score,
and recommend that its use primarily complements
individual needs-based suicide risk assessments. The use
of a continuous probability score is supported by its
calibration performance in external validation. The pos-
sibility of doing this is a clear advantage of our online risk
calculator. This approach would allow for the ﬂoor of
expertise to be raised, and provide a validated marker of
suicide risk to be added into other health and psychosocial
needs identiﬁed clinically. Further, it would allow for a
discussion between clinicians and their patients and car-
ers about their own risk level in a transparent manner.
Even with a focus on probabilities, it is possible that
someone with a predicted risk of 0% will die from suicide,
and clinical judgement will be required to determine
clinical management, and clear clinical indicators of risk
not captured in the tool should take priority. All included
risk factors were from routinely collected register data
and are likely to be known for most patients without
additional interviewing, thus the tool will have negligible
additional resource implications. Additionally, certain
variables have a broad categorical deﬁnition (education).
Nevertheless, some items can be marked as unknown, and
OxMIS provides a risk range, based on the lower and
upper bound of possible responses.
An important consideration will be how clinicians will
use such probability scores, and whether they will make
any impact to clinical management. These are empirical
questions that require further examination. However, one
promising approach suggested by an expert review that is
that low scores can assist clinical decision-making to
preserve resources by excluding low risk individuals in an
evidence-based way8. Although the negative predictive
value based at the 1% cut-off is not very different from the
Sensitivity: 58%
ty: 76%
AUC: 0.75
Sensitivity: 55%
ty: 75%
AUC: 0.71
a) Internal sample
b) External sample
Fig. 2 Suicide prediction model discrimination shown by
receiver-operating characteristics curves. a Internal sample and b
external sample. Sensitivity and speciﬁcity based on pre-speciﬁed 1%
cut-off
Table 3 True and false positive and negatives from
external validation (2 × 2 table)
Suicide No suicide Total
High risk 77 4105 4182
Low risk 62 12,143 12,205
Total 139 16,248 16,387
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pre-test probability, a tool provides a more transparent
approach, and one which is ﬂexible (i.e. clinical services
can decide on different thresholds depending on local
factors). Those identiﬁed using this suicide risk calculator
with higher risk scores, assessment without clear links to
improving clinical management will not reduce adverse
outcomes. At the same time, it is necessary to have a
validated risk assessment before consideration can be
given to linking the score to an intervention38. Developing
and validating a prediction model will necessarily precede
the next step of what is done to manage it. Possible
interventions that could be considered include increased
surveillance, psychological interventions, and service-
related changes. Non-harmful interventions should be
prioritised.
a) Derivation sample 
b) Validation sample 
Fig. 3 Calibration plots comparing predicted and observed risks of suicide in the derivation and validation sample of individuals with
severe mental illness. a Derivation sample and b validation sample. Individuals are grouped by predicted probability, and points are labelled with
the number of individuals in each grouping, and a 95% conﬁdence interval for the proportion of events in each group
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One of the main reasons for not using cut-off scores is
the low positive predictive value of 2%, which will mean
that most individuals who will be labelled high risk do not
subsequently die from suicide in the next year. Low
positive predictive values have also been shown in risk
assessment instruments in other populations12. In some
settings, high risk persons may be subject to additional
resources that may not be beneﬁcial or necessary (such as
inpatient admission). At the same time, using a cut-off of
1%, the tool accurately ruled out a large number of indi-
viduals—12,143 individuals in the validation sample of
16,387 or 74%—and hence could assist in preserving
healthcare resources by limiting the number of more
comprehensive suicide risk assessments. One of the
challenges faced by screening tools— the prevention
paradox that most suicides occur in low-risk individuals—
did not clearly apply even if the categorical score was
used. Of the suicides in the validation sample, 55% (77/
139) were correctly identiﬁed as high risk but nevertheless
45% (62/139 suicides) were in the low-risk group. But
another way of looking at this is that individuals with
predicted suicide risks of <5% contributed to nearly half
the suicides. This is one of the reasons why tools with
categories (such as low/high) have been criticised6, and
part of the rationale to remove categories in our online
calculator. At the same time, statistics such as positive and
negative predictive values depend on the threshold used,
which we pre-speciﬁed in a protocol, but could be
improved with different thresholds. Having a lower
threshold (such as 0.5%) will lead to a much higher
positive predictive value but at the cost of lower perfor-
mance in other metrics. This underscores our decision to
remove these categories in OxMIS. In summary, design-
ing any prognostic tool and deciding on how it will be
used will require an inevitable balance between over-
diagnosis (false positive predictions) and missing a diag-
nosis (false negative predictions). Both types of error can
cause signiﬁcant harm. Moreover, resources for support-
ing prevention of suicide are limited, and so targeting of
resources to high-risk patients is important. Our tool is
designed to be used in conjunction with assessing other
health and psychosocial needs, which would allow addi-
tional detection of high-risk individuals and in discussion
between clinicians, patients and carers.
In developing the score, risk factors for suicide were
tested on a sample of 58,771 patients using a multivariable
logistic regression model. This provides more precision
than in previous studies to markers of suicide in patients
with severe mental illness25,39 and contributes to the
growing evidence on risk factors for suicide16. The
strongest risk factors were being male (OR= 1.92,
1.58–2.33], being discharged from inpatient care (OR=
2.95, 2.45–3.55), previous self-harm (OR= 2.55,
2.09–3.11) and parental suicide (OR= 1.75, 1.29–2.38).
The inpatient risk factor adds to the evidence that points
towards the importance of improving the monitoring and
management of patients in the early period post-hospital
discharge with prompt follow-up, access to specialist
substance misuse services, and addressing the physical
safety of the local environment40,41. Social factors, such as
highest educational level, were associated with future
suicide risk42. Other risk factors identiﬁed in our cohort,
such as recent treatment with antipsychotics and anti-
depressants, are likely to be markers of illness severity,
and randomised controlled trials, which are not subject to
confounding by indication, have not shown increased
suicide risk in both medication classes43,44. The positive
association with previous alcohol use and comorbid
depression further highlights the need to treat co-
occurring conditions39. The ﬁndings of elevated risk in
individuals who have previously self-harmed are con-
sistent with population studies in Denmark2 and Swe-
den45. We investigated whether the diagnosis
(schizophrenia-spectrum vs. bipolar) was a candidate for
inclusion in the model but there was no signiﬁcant dif-
ference in risk by diagnosis in multivariable models. Other
models were considered, such as random forest and sto-
chastic gradient boosting, but do not provide a speciﬁc
prediction equation that can be used for out-of-sample
prediction, and hence cannot be translated into an online
calculator. Presenting the effects of individual risk factors
increases face validity as users are able to see the con-
tribution of factors (especially modiﬁable ones) to risk
prediction. We tested using a lasso to address possible
overﬁtting but found no material improvement in ﬁt.
A review of risk assessment tools found that almost all
examine self-harm rather than suicide as an outcome,
base their variable selection on face and content validity
rather than empirical derivation, and are used in indivi-
duals who have self-harmed8. Three empirically derived
tools, two Manchester self-harm rules and the RESH
score, have been developed to assess risk of repeat self-
harm in individuals presenting with self-harm to emer-
gency departments. Other tools have been developed with
speciﬁc populations, such as army veterans, and used a
wide range of 421 predictors in model derivation46. A
recent study aimed to use electronic health records to
predict suicidal behaviour in any patient accessing
healthcare in two Boston hospitals using more than 100
diagnoses and 100 medications in their models47. This US
study used a random split to generate a validation sample,
which meant that both samples would have been statis-
tically equivalent and the validation likely to perform
similar to the discovery sample. Further, it created a
model that uses laboratory ﬁndings, and is therefore not
scalable to community and other settings. In contrast, our
score uses mostly routinely collected factors in mental
health services, and we used an external validation that
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was geographical split, rather than randomly done.
Finally, a tool with good performance measures has been
designed to predict suicidal ideation and attempts48, and
tested in adolescents, individuals in an antidepressant
trial, and attending emergency departments, but not in
speciﬁc diagnostic groups like schizophrenia-spectrum
and bipolar disorders, and not for completed suicide.
Some limitations of the current model should be noted. A
further limitation is that we did not test information about
symptoms, including suicidal thoughts and plans, which
were not available in the registers used. Whether these
items improve prediction incrementally when the other
risk factors are already in a model is an empirical ques-
tion, and may come with additional costs by making a tool
longer and potentially requiring additional assessment.
Further, the ﬂuctuating nature and high prevalence of
certain symptoms (including suicidal ideas) may mean
that their predictive value is low. At the same time, it is
possible that additional factors could improve this score,
which future research can consider42. Prediction based on
a narrow set of 4–5 risk factors has been shown to have
limited utility in general population settings49, but the
OxMIS score includes more items (17 in total) than
current approaches and has been derived in a speciﬁc
clinical population with higher risks than community
persons. Missing data for some risk factors required
multiple imputation to be used for model development.
Although this allowed a larger sample to be used in model
ﬁtting, we cannot rule out that the model performance
may have been better if complete data had been available.
Finally, this model has few dynamic variables (recent
medication use, past drug use disorder, past alcohol use
disorder, comorbid depression, and possibly previous self-
harm, and inpatient status) and this is a limitation, and
new technologies may assist in developing new scores that
reliably incorporate more dynamic risk factors. However,
more complex models can risk over-ﬁtting predictions to
the speciﬁc dataset so that prediction accuracies are
greatly reduced when applied to new populations, and
may reduce the ability to facilitate discussions between
clinicians and their patients about their risk in a trans-
parent manner.
Before implementation of any such tool in clinical
practice, external validation should be undertaken, and
also examining how interventions can be linked to this
risk calculator. Such external validation will provide
feedback on its acceptability in clinical practice and
whether probability scores supplement clinical decision-
making, although data will not be harvested from the
online tool as it is not known who will use it. Researchers
may use OxMIS to provide baselines risks for clinical
research studies. Ultimately, though, testing in RCTs will
be required to see whether its use will reduce suicide
rates. Furthermore, a prediction score for risk of non-fatal
self-harm could be developed in this patient population.
In summary, we have developed and validated a clinical
risk prediction score in individuals with schizophrenia-
spectrum or bipolar disorder with good measures of dis-
crimination and calibration. This has been translated into
an online calculator providing probability scores, which
can be used by healthcare staff to assist in clinical
decision-making.
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